Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $55M Series B (Jan 2026). 500% ARR growth since prior round. Fortune 500 adoption up 250%. Customers include Uber, Shopify, Atlassian, Reddit, Canva. AI contract review with lawyer-built playbooks.
Ivo is an AI contract review and intelligence platform that converts legal agreements into structured, searchable data using playbooks built and validated by lawyers — a bottom-up approach that ensures the AI extracts what actually matters in contracts rather than what NLP models assume is important. The company raised $55 million in Series B financing in January 2026, reporting 500% ARR growth since its prior round and 250% growth in Fortune 500 customer adoption. Customers include Uber, Shopify, Atlassian, Reddit, and Canva.
Thomson Reuters (NYSE: TRI) Westlaw legal research platform with CoCounsel AI ($650M Casetext acquisition); KeyCite citation analysis competing with LexisNexis and Harvey.ai for attorney AI legal research market leadership.
Westlaw is a legal research platform owned by Thomson Reuters (NYSE: TRI) — a Toronto, Canada-based information and professional services company generating $6.8+ billion in annual revenue across legal, financial, and risk intelligence segments — providing attorneys, judges, law students, and legal researchers with the most comprehensive legal research database in the US and internationally, offering access to case law dating to the 1800s, statutes, regulations, administrative law, secondary sources (law review articles, practice guides, treatises), and the KeyCite citation analysis tool that verifies whether a legal precedent remains good law and identifies all citing references. Westlaw is one of the two dominant legal research platforms globally (alongside LexisNexis) with the subscription legal research market generating $5B+ annually from law firms, corporate legal departments, courts, and law schools.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.